Stock Events

Stock Events

BioVie 

$0.28
59
-$0.07-20% Thursday 19:27

Statistics

Day High
0.3
Day Low
0.26
52W High
0.25
52W Low
0.25
Volume
9,688
Avg. Volume
-
Mkt Cap
2.11M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

3JunExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-1.82
-1.46
-1.09
-0.73
Expected EPS
-0.73
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-35.82MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BIVIW. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Madrigal Pharmaceuticals
MDGL
Mkt Cap11.92B
Madrigal Pharmaceuticals is focused on developing therapies for NASH, directly competing with BioVie's liver disease portfolio.
Viking Therapeutics
VKTX
Mkt Cap3.97B
Viking Therapeutics is working on treatments for metabolic and endocrine disorders, including NASH, making it a direct competitor to BioVie.
Gilead Sciences
GILD
Mkt Cap172.51B
Gilead Sciences has a broad portfolio of liver disease treatments, including for NASH and hepatitis, competing with BioVie's offerings.
Agios Pharmaceuticals
AGIO
Mkt Cap1.93B
Agios Pharmaceuticals focuses on metabolic disorders, including those affecting the liver, positioning it as a competitor to BioVie.
Galmed Pharmaceuticals
GLMD
Mkt Cap4.89M
Galmed Pharmaceuticals is developing therapies for liver diseases like NASH, competing in the same space as BioVie.
Enanta Pharmaceuticals
ENTA
Mkt Cap414.11M
Enanta Pharmaceuticals is engaged in developing treatments for liver diseases, including NASH, directly competing with BioVie.
Abbvie
ABBV
Mkt Cap367.8B
AbbVie has a diverse portfolio that includes treatments for liver diseases, competing with BioVie in the broader liver disease market.

About

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.
Show more...
CEO
Mr. Cuong Viet Do M.B.A.
Employees
14
Country
United States
ISIN
US09074F1738

Listings

XNAS
US
BIVIW
XNAS
US
BIVI
BOATS
BOATS
BIVI.BOATS

0 Comments

Share your thoughts

FAQ

What is BioVie stock price today?▼
The current price of BIVIW is $0.28 USD — it has decreased by -20% in the past 24 hours. Watch BioVie stock price performance more closely on the chart.
What is BioVie stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange BioVie stocks are traded under the ticker BIVIW.
What is BioVie market cap?▼
Today BioVie has the market capitalization of 2.11M
When is the next BioVie earnings date?▼
BioVie is going to release the next earnings report on June 03, 2026.
What is BioVie revenue for the last year?▼
BioVie revenue for the last year amounts to 0 USD.
What is BioVie net income for the last year?▼
BIVIW net income for the last year is -35.82M USD.
How many employees does BioVie have?▼
As of April 17, 2026, the company has 14 employees.
In which sector is BioVie located?▼
BioVie operates in the Health & Wellness sector.
When did BioVie complete a stock split?▼
BioVie has not had any recent stock splits.
Where is BioVie headquartered?▼
BioVie is headquartered in Carson City, United States.